Breast Cancer Breakthroughs: ASCO 2026 Highlights

Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ASCO26.


2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Ana C. Garrido-Castro, MD

Ana C. Garrido-Castro, MD

Medical Oncology

2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Adrienne Waks, MD

Adrienne Waks, MD

Medical Oncology

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Adrienne Waks, MD

Adrienne Waks, MD

Medical Oncology

2026 ASCO Breast Cancer Highlights: BWEL

Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Jennifer Ligibel, MD

Jennifer Ligibel, MD

Medical Oncology

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Ana C. Garrido-Castro, MD

Ana C. Garrido-Castro, MD

Medical Oncology

2026 ASCO Breast Cancer Highlights: persevERA

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial and oral SERDS in metastatic breast cancer.
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Erica Mayer, MD, MPH

Erica Mayer, MD, MPH

Medical Oncology

2026 ASCO Breast Cancer Highlights: Food Access, Poverty, and MBC

Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and ...
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Rachel Freedman, MD

Rachel Freedman, MD

Medical Oncology

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

ASCO 2026 Highlights Panel Discussion

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Erica Mayer, MD, MPH; and Jennifer Ligibel, MD, discuss important breast cancer research presented at the 2026 ASCO Annual Meeting.
Harold Burstein, MD, PhD

Harold Burstein, MD, PhD

Medical Oncology
Sara Tolaney, MD, MPH

Sara Tolaney, MD, MPH

Medical Oncology
Nancy Lin, MD

Nancy Lin, MD

Medical Oncology
Erica Mayer, MD, MPH

Erica Mayer, MD, MPH

Medical Oncology
Jennifer Ligibel, MD

Jennifer Ligibel, MD

Medical Oncology